UPLC-MS/MS to Support Preclinical and Clinical Antiretroviral Pharmacology Studie

UPLC-MS/MS 支持临床前和临床抗逆转录病毒药理学研究

• 批准号: 8051351
• 负责人: Angela D Kashuba
• 金额: $ 38.76万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8051351
• 关键词: AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Analytical Chemistry; Anti-Retroviral Agents; Area; Basic Science; Businesses; Capital; Clinical; Clinical Pharmacology; Clinical Sciences; Economics; Ensure; Extramural Activities; Family health status; Fees; Foundations; Funding; Genital system; Growth; Housing; Institutes; Institution; International; Maintenance; North Carolina; Occupations; Pharmacology; Pharmacy Schools; Recovery; Research; Research Personnel; System; Technology; Time; United States National Institutes of Health; Universities; Workload; cost; innovation; instrument; instrumentation; mouse model; peer; pre-clinical; success

DESCRIPTION (provided by applicant): The purpose of this proposal is to provide a second dedicated UPLC-MS/MS instrument to the established Clinical Pharmacology and Analytical Chemistry Core (CPACC) of the University of North Carolina at Chapel Hill (UNC-CH) Center for AIDS Research (CFAR). The CPACC has an 11-year record of providing a state-of- the-art centralized CLIA-certified unit to sustain the pharmacology and analytical studies of HIV/AIDS related clinical and basic science research at UNC-CH, the collaborating institutions of Family Health International and Research Triangle Institute, and to extramural CFARs. The success of the CPACC is best exemplified by the outstanding score it received from peer reviewers during the UNC CFAR's five-year renewal in 2005 for support of domestic and international investigators through analytical innovation. Since that time, the CPACC has continued to grow, and now assists more than 50 users per year. The CPACC has demonstrated success on the Agilent 6410A Triple Quadrupole LC-MS/MS System purchased in 2007. This instrument is being used full-time for network HIV prevention studies. Because of this workload, and due to lack of additional instrumentation, other key projects requiring MS/MS technology (eg humanized mouse model pharmacology for HIV prevention and cure, cellular pharmacology of antiretrovirals in the genital tract) are either on hold, or are being turned down. The addition of a second UPLC-MS/MS instrument will support NIH-funded CFAR investigators to ensure that their projects can be completed quickly and efficiently, will create job opportunities for those in the Research Triangle Area, will provide capital to local businesses, and build a foundation for longer-term economic growth within the UNC-CH system. A cost recovery fee plan guarantees the financial viability for the instrument. Dr. Angela DM Kashuba (Director of the CPACC) serves as PI of the proposal and will be responsible for all aspects of instrument maintenance and efficient usage in generating new bioanalytical innovations. The instrument will be housed in the School of Pharmacy with the other analytical instruments of the CPACC.

描述(由申请人提供)：本提案的目的是为北卡罗来纳大学教堂山分校(UNC-CH)艾滋病研究中心(CFAR)建立的临床药理学和分析化学核心(CPACC)提供第二个专用的UPLC-MS/MS仪器。CPACC拥有11年的记录，提供最先进的中央CLIA认证单位，以支持北卡罗来纳大学-CH、国际家庭健康合作机构和三角研究所的艾滋病毒/艾滋病相关临床和基础科学研究的药理学和分析研究，以及外部CFAR。CPACC的成功最好的例证是，在2005年通过分析创新支持国内和国际调查人员的五年续展期间，该委员会从同行审查员那里获得了突出的分数。从那时起，CPACC持续增长，现在每年帮助50多名用户。CPACC在2007年购买的安捷伦6410A三重四极杆LC-MS/MS系统上取得了成功。该仪器正被全职用于网络艾滋病毒预防研究。由于这一工作量，以及由于缺乏额外的仪器，其他需要MS/MS技术的关键项目(如防治艾滋病毒的人源化小鼠模型药理学、生殖道抗逆转录病毒药物的细胞药理学)要么被搁置，要么被拒绝。第二台UPLC-MS/MS仪器的增加将支持NIH资助的CFAR调查人员确保他们的项目能够快速有效地完成，将为研究三角地区的调查人员创造就业机会，将为当地企业提供资本，并为北卡罗来纳大学-CH系统内的长期经济增长奠定基础。成本回收费用计划保证了该工具的财务可行性。安吉拉·DM·卡舒巴博士(CPACC主任)担任该提案的PI，将负责仪器维护和有效使用的所有方面，以产生新的生物分析创新。该仪器将与CPACC的其他分析仪器一起存放在药学院。